Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.48 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.48 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | IDH1 | O75874 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20677088 | 0.88 | KDM2B (0.46) | KDM2BPHF8KDM2AIDO1MGLL | |
| SCHEMBL27661890 | 0.88 | KDM2B (0.46) | KDM2BPHF8KDM2AIDO1MGLL | |
| SCHEMBL19402169 | 0.88 | KDM2B (0.46) | KDM2BPHF8KDM2AIDO1MGLL | |
| SCHEMBL21668010 | 0.80 | MAP4K4 (0.42) | PHF8NOTUMIDH1 | |
| SCHEMBL22185889 | 0.80 | ALDH1A1 (0.46) | MGLLFGFR1NOTUMMAPT | |
| SCHEMBL12443627 | 0.80 | CYP2E1 (0.42) | GAA | |
| SCHEMBL944327 | 0.80 | PARP1 (0.48) | FGFR1GAA | |
| SCHEMBL25590434 | 0.79 | GRM5 (0.59) | NOTUMKDM4EMAPT | |
| SCHEMBL12146179 | 0.79 | KDM2B (0.55) | KDM2BPHF8KDM2AIDO1FGFR1 | |
| SCHEMBL27681837 | 0.78 | TSHR (0.42) | KDM2BPHF8KDM2AIDO1NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200206233-A1 | HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS | INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) | 2020-07-02 | — | — | US | disclosed |
| EP-3429355-B1 | SUBSTITUTED SULFONYLAMIDE FOR COMBATING ANIMAL PESTS | BAYER CROPSCIENCE AG (DE) | 2020-02-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200206233-A1 | HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS | IDH1, IDH2, IDH3A | KDM2B 505/4885PHF8 653/4885KDM2A 424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.